Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017160 (
gastroenteritis
)
11,398
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Water-soluble derivatives of camptothecin, and active topoisomerase I inhibitor, have shown a broad spectrum of activity against human tumors. Early clinical trials with the water-soluble sodium salt of camptothecin were hindered by significant cystitis,
gastroenteritis
, and leukopenia. Furthermore, the sodium salt of camptothecin has been shown to have significantly less activity than the water-insoluble lactone form of the compound. We describe a formulation of lipid-complexed
CPT
(LC-
CPT
; particle size range 20.8-208.1 nm) that is very easy to prepare and allows for intravenous administration in vivo in clinically relevant lipid-drug ratios (12.5:1 w/w). The lipid formulation had in vitro antitumor activity similar to that of
CPT
formulated without lipids and displayed similar cytotoxicity against MDR-1-negative and -positive tumor cells. The biodistribution of
CPT
was profoundly affected by lipid complexation; free
CPT
achieved the greatest concentration in the pulmonary parenchyma while LC-
CPT
achieved the highest concentration in the gastrointestinal tract. LC-
CPT
had significant antitumor activity in vivo against intraperitoneal L1210 and P338 leukemia and appeared to be more potent then free
CPT
.
...
PMID:Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. 861 6
We report a patient with
carnitine palmitoyltransferase I
(CPT I) deficiency, who presented with acute encephalopathy at 6 months of age. This was precipitated by an episode of
gastroenteritis
. No hypoglycaemia was documented, but there was hepatomegaly; blood tests revealed raised transaminases, a coagulopathy and severe hypertriglyceridaemia (48.8 mmol/L) and hypercholesterolaemia (9.5 mmol/L). The hyperlipidaemia resolved within 3 days of treatment and did not recur. At 2 years of age, the patient's liver function, growth and development are all normal. Hyperlipidaemia has been reported during acute illness in previous patients with CPT I deficiency but it is not a well-recognized feature; it should alert metabolic specialists to this potential diagnosis.
...
PMID:Hyperlipidaemia due to carnitine palmitoyltransferase I deficiency. 1716 Jun 14